Breakthrough Dual-Action Antibiotic Could Halt Bacterial Resistance

University of Illinois Chicago researchers unveil macrolones, a new class of antibiotics targeting two bacterial processes simultaneously.

Macrolones combine the mechanisms of macrolides and fluoroquinolones, disrupting protein production and DNA structure.
Targeting both bacterial ribosomes and DNA gyrase makes it nearly impossible for bacteria to develop resistance.
Researchers estimate the dual-action approach increases the difficulty of bacterial resistance evolution by 100 million times.
The study highlights the importance of interdisciplinary collaboration in advancing antibiotic development.
Further optimization and development are needed before macrolones can be used in clinical settings.